Twinrix Junior Vaccine Injection
hepatitis A + Hepatitis B vaccine
"360 Elisa, 10mcg/0.5ml"
GLAXOSMITHKLINE BIOLOGICALS S.A.
| Pack size | 1 Dose (0.5ml) Prefilled Syringe |
|---|---|
| Dispensing mode | POM |
| Source | BELGIUM |
| Agent | GULF DRUG EST. |
| Retail Price | 83.50 AED |
Available as:
Indications
Twinrix Junior Vaccine Injection is used for:
active immunisation against hepatitis A and hepatitis B virus infection
Adult Dose
Standard schedule:
The immunogenicity of TWINRIX (720/20) has been investigated using a 0, 1 and 6 month vaccination schedule in randomised clinical studies involving over 700 adult volunteers.
Specific humoral antibodies (seropositivity) against HAV were elicited in:
# 92-96% of vaccinees one month after the first dose
# 97-100% of vaccinees one month after the second dose
# 100% of vaccinees one month after the third dose.
Seropositivity was defined as anti-HAV antibody titres >= 33 IU/L.
Seroprotective levels of anti-HBs antibodies (titers >=10 IU/L) were elicited in:
# 33.7% of vaccinees one month after the first dose
# 83.9% of vaccinees one month after the second dose
# 99.3% of vaccinees one month after the third dose.
An anti-HBs antibody titre above 10 IU/L correlates with protection against hepatitis B infection.
Rapid Schedule:
The immunogenicity of TWINRIX (720/20) has also been investigated using a 0, 7, 21 day primary
schedule plus a fourth dose at month 12 in a randomised clinical study involving over 400 adult
volunteers, of whom 239 received TWINRIX (720/20).
Specific humoral antibodies (seropositivity) against HAV were elicited in:
# 100% of vaccinees one week after the third dose
# 99.5% of vaccinees five weeks after the third dose
# 100% of vaccinees one month after the fourth dose.
Seroprotective levels of anti-HBs antibodies (titers >=10 IU/L) were elicited in:
# 82% of vaccinees one week after the third dose
# 85% of vaccinees five weeks after the third dose
# 100% of vaccinees one month after the fourth dose.
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
should be used during pregnancy only when clearly needed, and when the possible advantages outweigh the possible risks for the foetus.
The effect on embryo-foetal, peri-natal and post-natal survival and development has not been prospectively evaluated in clinical trials.
Interactions
Adverse Effects
Side effects of hepatitis A + Hepatitis B vaccine :
Gastrointestinal disorders: Common: gastrointestinal symptoms (such as diarrhoea, nausea,
vomiting)
General disorders and administration site conditions: Very common: pain and redness at the
injection site, fatigue; Common: injection site reaction, malaise, swelling at the injection site;
Uncommon: fever (≥ 37.5˚C); Rare: influenza like illness, chills
Infections and infestations: Common: Viral infection; Uncommon: upper respiratory tract infection
Blood and lymphatic system disorders: Rare: lymphadenopathy
Metabolism and nutrition disorders: Rare: decreased appetite
Nervous system disorders: Very common: headache; Uncommon: dizziness; Rare:
hypoaesthesia, paraesthesia
Vascular disorders: Rare: hypotension
Skin and subcutaneous tissue disorders: Rare: rash, pruritus; Very rare: urticaria
Musculoskeletal and connective tissue disorders: Uncommon: myalgia; Rare: arthralgia
Mechanism of Action
Note
Twinrix Junior Vaccine "360 Elisa, 10mcg/0.5ml" Injection manufactured by GLAXOSMITHKLINE BIOLOGICALS S.A.. Its generic name is hepatitis A + Hepatitis B vaccine. Twinrix Junior Vaccine is availble in United Arab Emirates.
Farmaco UAE drug index information on Twinrix Junior Vaccine Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.